ATE401908T1 - Pharmazeutische zusammensetzungen von erythropoietin - Google Patents

Pharmazeutische zusammensetzungen von erythropoietin

Info

Publication number
ATE401908T1
ATE401908T1 AT00921929T AT00921929T ATE401908T1 AT E401908 T1 ATE401908 T1 AT E401908T1 AT 00921929 T AT00921929 T AT 00921929T AT 00921929 T AT00921929 T AT 00921929T AT E401908 T1 ATE401908 T1 AT E401908T1
Authority
AT
Austria
Prior art keywords
erythropoietin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
AT00921929T
Other languages
English (en)
Inventor
Wing Cheung
Jaya Natarajan
Marilyn Sanders
Els Vercamen
Basant Sharma
Selima Begun
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE401908T1 publication Critical patent/ATE401908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00921929T 1999-04-09 2000-04-07 Pharmazeutische zusammensetzungen von erythropoietin ATE401908T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
ATE401908T1 true ATE401908T1 (de) 2008-08-15

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921929T ATE401908T1 (de) 1999-04-09 2000-04-07 Pharmazeutische zusammensetzungen von erythropoietin

Country Status (27)

Country Link
US (2) US6696056B1 (de)
EP (1) EP1181036B1 (de)
JP (1) JP2002541208A (de)
KR (1) KR100740794B1 (de)
CN (1) CN1165339C (de)
AR (1) AR029623A1 (de)
AT (1) ATE401908T1 (de)
AU (1) AU775041B2 (de)
BG (1) BG106046A (de)
BR (1) BR0010665A (de)
CA (1) CA2369444C (de)
CY (1) CY1108418T1 (de)
DE (1) DE60039598D1 (de)
DK (1) DK1181036T3 (de)
ES (1) ES2308978T3 (de)
HK (1) HK1041445B (de)
HU (1) HUP0201068A3 (de)
IL (1) IL145816A0 (de)
MX (1) MXPA01010208A (de)
NO (1) NO20014893L (de)
NZ (1) NZ515380A (de)
PL (1) PL203797B1 (de)
PT (1) PT1181036E (de)
RU (1) RU2225221C2 (de)
TR (1) TR200103788T2 (de)
WO (1) WO2000061169A1 (de)
ZA (1) ZA200109236B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
NZ543859A (en) * 2003-06-10 2008-01-31 Lg Life Sciences Ltd Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1789074A4 (de) * 2004-08-09 2009-08-12 Alios Biopharma Inc Synthetische hyperglycosylierte, protease-resistente polypeptid-varianten, orale formulierungen und anwendungsverfahren dafür
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EP3528787B1 (de) 2016-10-21 2026-01-07 Amgen Inc. Pharmazeutische formulierungen und verfahren zur herstellung davon
US11667686B2 (en) 2017-06-06 2023-06-06 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin

Also Published As

Publication number Publication date
EP1181036A1 (de) 2002-02-27
US20040248797A1 (en) 2004-12-09
CN1354669A (zh) 2002-06-19
MXPA01010208A (es) 2003-07-21
IL145816A0 (en) 2002-07-25
HK1041445B (en) 2009-07-03
NO20014893L (no) 2001-11-15
CA2369444A1 (en) 2000-10-19
US6696056B1 (en) 2004-02-24
CA2369444C (en) 2009-08-18
ZA200109236B (en) 2003-12-08
NO20014893D0 (no) 2001-10-08
CY1108418T1 (el) 2014-04-09
CN1165339C (zh) 2004-09-08
EP1181036A4 (de) 2004-04-21
AU4218600A (en) 2000-11-14
PL203797B1 (pl) 2009-11-30
AU775041B2 (en) 2004-07-15
BG106046A (en) 2002-05-31
PT1181036E (pt) 2008-10-03
ES2308978T3 (es) 2008-12-16
TR200103788T2 (tr) 2002-05-21
HUP0201068A2 (en) 2002-08-28
KR100740794B1 (ko) 2007-07-20
WO2000061169A1 (en) 2000-10-19
AR029623A1 (es) 2003-07-10
HK1041445A1 (en) 2002-07-12
BR0010665A (pt) 2004-03-09
EP1181036B1 (de) 2008-07-23
NZ515380A (en) 2003-10-31
RU2225221C2 (ru) 2004-03-10
JP2002541208A (ja) 2002-12-03
HUP0201068A3 (en) 2002-10-28
KR20020016770A (ko) 2002-03-06
PL351837A1 (en) 2003-06-16
DE60039598D1 (de) 2008-09-04
DK1181036T3 (da) 2008-11-24

Similar Documents

Publication Publication Date Title
DE60039598D1 (de) Pharmazeutische zusammensetzungen von erythropoietin
NO20015175L (no) Farmasöytisk sammensetning
FI991485L (fi) Uusi farmaseuttinen koostumus
PT1242087E (pt) Composicoes farmaceuticas
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE246490T1 (de) Pharmazeutische zusammensetzung von topiramate
IS5046A (is) Lyfjasamsetningar
DE60033021D1 (de) Strukturierte kosmetische zusammensetzungen
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
EE05020B1 (et) Glburiidi ravimkoostis
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
EP1408896A4 (de) Pharmazeutische zusammensetzung
PT1239832E (pt) Composicoes farmaceuticas
ID30032A (id) Formulasi farmasi
IS2515B (is) Lyfjasamsetningar
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200000330A (et) Farmatseutilised kompositsioonid
PT1051156E (pt) Composicoes farmaceuticas
NO20004816D0 (no) Ny farmasøytisk formulering
NO994436D0 (no) Farmasöytiske sammensetninger
ITMI992202A0 (it) Composizioni farmaceutiche contenenti farmaci antiinfiammatori
FI981567A0 (fi) Farmaseuttiset koostumukset
SE9800330D0 (sv) Pharmaceutical compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181036

Country of ref document: EP